Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamikibart + Ranibizumab in Diabetic Macular Edema
NCT05151744Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of vamikibart in diabetic macular edema (DME) (2 arms), sponsored by Roche. Primary endpoint: Change From Baseline in Best Corrected Visual Acuity Averaged Over Week 44 and Week 48 in Treatment-naïve Participants. Started Dec 2021; status: completed.
02
Drugs
vamikibart
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05151744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151744.